Jasper Therapeutics (JSPR) Competitors

$23.02
+0.18 (+0.79%)
(As of 05/17/2024 ET)

JSPR vs. DCGO, AVXL, CRBU, MGTX, SOPH, TNYA, CADL, BDTX, IVVD, and ADAP

Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include DocGo (DCGO), Anavex Life Sciences (AVXL), Caribou Biosciences (CRBU), MeiraGTx (MGTX), SOPHiA GENETICS (SOPH), Tenaya Therapeutics (TNYA), Candel Therapeutics (CADL), Black Diamond Therapeutics (BDTX), Invivyd (IVVD), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "medical" sector.

Jasper Therapeutics vs.

Jasper Therapeutics (NASDAQ:JSPR) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.

Jasper Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, DocGo has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Jasper Therapeutics currently has a consensus price target of $64.29, indicating a potential upside of 179.26%. DocGo has a consensus price target of $7.75, indicating a potential upside of 151.62%. Given Jasper Therapeutics' higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than DocGo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jasper Therapeutics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
DocGo
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

DocGo has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/A-$64.46M-$5.63-4.09
DocGo$703.37M0.46$6.86M$0.2015.40

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by insiders. Comparatively, 13.8% of DocGo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

DocGo received 15 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 83.87% of users gave Jasper Therapeutics an outperform vote while only 73.21% of users gave DocGo an outperform vote.

CompanyUnderperformOutperform
Jasper TherapeuticsOutperform Votes
26
83.87%
Underperform Votes
5
16.13%
DocGoOutperform Votes
41
73.21%
Underperform Votes
15
26.79%

DocGo has a net margin of 2.98% compared to Jasper Therapeutics' net margin of 0.00%. DocGo's return on equity of 6.20% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A -64.58% -56.15%
DocGo 2.98%6.20%4.14%

In the previous week, Jasper Therapeutics had 6 more articles in the media than DocGo. MarketBeat recorded 24 mentions for Jasper Therapeutics and 18 mentions for DocGo. Jasper Therapeutics' average media sentiment score of 0.92 beat DocGo's score of 0.59 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jasper Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DocGo
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

DocGo beats Jasper Therapeutics on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JSPR vs. The Competition

MetricJasper TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$346.68M$2.92B$5.10B$7.94B
Dividend YieldN/A2.18%37.44%3.91%
P/E Ratio-4.0929.89178.7418.78
Price / SalesN/A322.672,396.33111.81
Price / CashN/A172.8736.5632.08
Price / Book3.066.655.734.68
Net Income-$64.46M-$42.18M$104.88M$217.01M
7 Day Performance7.92%3.93%1.87%2.90%
1 Month Performance-0.82%9.36%4.76%6.58%
1 Year Performance29.33%7.91%7.73%10.15%

Jasper Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DCGO
DocGo
3.8898 of 5 stars
$3.08
-12.0%
$10.58
+244.2%
-64.8%$320.33M$624.29M43.934,164Short Interest ↓
AVXL
Anavex Life Sciences
3.619 of 5 stars
$3.88
+4.6%
$40.00
+930.9%
-52.1%$318.60MN/A-7.1940
CRBU
Caribou Biosciences
1.9562 of 5 stars
$3.65
+4.3%
$22.50
+516.4%
-22.8%$329.67M$34.48M-2.52158Analyst Forecast
Short Interest ↓
News Coverage
MGTX
MeiraGTx
3.9863 of 5 stars
$5.10
-0.8%
$25.67
+403.3%
-25.8%$330.54M$14.02M-3.47419
SOPH
SOPHiA GENETICS
1.5439 of 5 stars
$4.82
+4.8%
$8.00
+66.0%
+6.8%$314.41M$62.37M-3.95430Gap Down
High Trading Volume
TNYA
Tenaya Therapeutics
2.1411 of 5 stars
$4.48
-0.7%
$15.40
+243.8%
-34.8%$351.77MN/A-2.68140Analyst Forecast
Analyst Revision
News Coverage
CADL
Candel Therapeutics
0.6123 of 5 stars
$9.97
-7.9%
$11.00
+10.3%
+637.2%$292.62M$120,000.00-7.6742Gap Up
BDTX
Black Diamond Therapeutics
2.2431 of 5 stars
$6.75
-2.7%
$12.25
+81.5%
+181.5%$354.58MN/A-3.5954Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
Positive News
IVVD
Invivyd
1.677 of 5 stars
$2.42
-4.3%
$11.33
+368.3%
+57.9%$288.52MN/A-1.3494Analyst Forecast
Analyst Revision
News Coverage
ADAP
Adaptimmune Therapeutics
1.0872 of 5 stars
$1.14
flat
$2.50
+119.3%
-17.2%$281.38M$60.28M-2.07449Analyst Forecast
Analyst Revision
News Coverage

Related Companies and Tools

This page (NASDAQ:JSPR) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners